- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 6
The Center for Biosimilars® recaps the top stories for the week of January 6.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 6, 2019.
Number 5: A recent study finds that peer influence factors heavily into whether oncologists decide to adopt bevacizumab for their patients.
Number 4: The FDA notes the approval of 10 biosimilars in its 2019 report of drug approvals, which included 48 novel drugs.
Number 3: A look back at the top 5 legal stories in 2019 finds that cases involving adalimumab featured in 2 of them.
Number 2: Novo Nordisk takes 3 steps to improve insulin affordability, and says the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.
Number 1: Pfizer says it is launching its bevacizumab biosimilar, Zirabev, in the United States.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
